BenevolentAI Investor Day Presentation Deck
BEN-8744 - Best-in-class, oral, peripherally restricted potent and
selective drug for the treatment of Moderate-Severe UC
• Phosphodiesterase 10 (PDE10) was identified by our
TargetID platform as an entirely novel target for the
treatment of UC/IBD
• Using our Molecular Design expertise we optimally
designed a best in class peripherally restricted PDE10
inhibitor: BEN-8744
• BEN-8744 is expected to provide an efficacious disease
modifying oral treatment for UC/IBD
• BEN-8744 will target Moderate and Severe UC/IBD
patients, meeting the unmet need left by existing
therapies including:
o Patients refractory to anti-TNFS or other biologics
o Improved safety and tolerability profile compared to
competitors
o A Precision Medicine approach to target key
responder patient cohorts, avoiding the safety risks
associated with ineffective therapies
An opportunity to differentiate on safety,
efficacy and a precision medicine approaches
Drug
Zeposia (Ozanimod)
Etrasimod
Jyseleca (Filgotinib)
Rinvoq
(Upadacitinib)
TD-1473
Company
BMS
Arena
Galapagos
& Gilead
Abbvie
Theravance
& Janssen
MOA
SIP1 receptor
agonist
SIP1 receptor
agonist
JAK1 inhibitor
JAKI inhibitor
Pan-JAK inhibitor
(gut-selective)
Safety
• S1P1 agonists are
associated with
immunosuppression
and anaemia
JAK inhibitors carry a
black box health.
warning
Benevolent 61View entire presentation